P080 Therapeutical effect of urine-derived stem cells on DSS-induced chronic model of mice

X.R. Wu, C. Zhou, H.S. Liu, L. Xuan-hui, T. Hu, X.B. Zheng, Z.X. Liang, X.J. Wu, X. Gao, X.S. He, J. Ke, Y.F. Chen, X.W. He, J.C. Hu, Y. Zou, P. Lan

The Sixth Affiliated Hospital, Sun Yat-Sen University South Campus, Department of Colorectal Surgery, Guangzhou, China


The application of stem cell therapy in the treatment of inflammatory bowel diseases (IBD) is limited because of the invasive approaches of stem cells. Urine-derived stem cells (USCs) were recently shown to have regenerative properties, which can be harvested in a safe, low-cost and non-invasive way.


Human USC were isolated and expanded from the urine of healthy male adult volunteers (n = 3, age arrange 24–30 years old). USC were characterised by cell surface marker expression profile and multipotent differentiation. In vivo therapeutic value of USC was assessed using murine colitis chronic model induced by dextran sulphate sodium (DSS).


USC were positive for mesenchymal stem cell markers but were negative for hematopoietic stem cell markers. These cells differentiated into osteo-, adipo- and chondro-genic cell lineages. Systemic administration of USC significantly ameliorated the clinical and histopathological severity of colitis and increased the survival rate in chronic murine colitis model.


This study demonstrated that implantation of USC reduces inflammation in IBD rodent model, indicating that USC therapy serves as a potential cell-based therapeutic candidate for IBD.